United Therapeutics
Clinical trials sponsored by United Therapeutics, explained in plain language.
-
New hope to slow deadly lung disease progression
Disease control CompletedThis study tested whether adding a new drug called ralinepag to standard treatments could help people with pulmonary arterial hypertension (PAH), a serious lung and heart condition. It involved 687 adults with PAH who were already on stable medication. The main goal was to see if…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New inhaled therapy tested to slow scarring lung disease
Disease control CompletedThis study tested whether an inhaled medication called treprostinil could help slow the decline of lung function in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. About 600 participants were randomly assigned to receive either the active drug or…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC